MedKoo Cat#: 584328 | Name: Viprostol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Viprostol is a prostaglandin antihypertensive.

Chemical Structure

Viprostol
Viprostol
CAS#73621-92-8

Theoretical Analysis

MedKoo Cat#: 584328

Name: Viprostol

CAS#: 73621-92-8

Chemical Formula: C23H36O5

Exact Mass: 392.2563

Molecular Weight: 392.54

Elemental Analysis: C, 70.38; H, 9.24; O, 20.38

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Viprostol; CL 115,347
IUPAC/Chemical Name
Prosta-5,13-dien-1-oic acid, 16-ethenyl-11,16-dihydroxy-9-oxo-, methyl ester, (5Z,11alpha,13E)-
InChi Key
TWCQWABAGCMHLL-ROVQGQOSSA-N
InChi Code
InChI=1S/C23H36O5/c1-4-6-15-23(27,5-2)16-11-13-19-18(20(24)17-21(19)25)12-9-7-8-10-14-22(26)28-3/h5,7,9,11,13,18-19,21,25,27H,2,4,6,8,10,12,14-17H2,1,3H3/b9-7-,13-11+/t18-,19-,21-,23?/m1/s1
SMILES Code
CCCCC(O)(C=C)C/C=C/[C@@H]1[C@H](C(C[C@H]1O)=O)C/C=C\CCCC(OC)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 392.54 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chan PS, Cervoni P, Scully PA, Ronsberg MA, Accomando RC. Mechanism of action of a new prostaglandin antihypertensive, viprostol [CL 115 347; (dl)-15-deoxy-16-hydroxy-16(alpha/beta)-vinyl-prostaglandin E2 methyl ester]: (I). Vasodilation. J Hypertens. 1986 Dec;4(6):741-7. PubMed PMID: 3029218. 2: Chan PS, Cervoni P, Accomando RC, Quirk GJ, Ronsberg MA. Mechanism of action of a new prostaglandin antihypertensive, viprostol [CL 115 347; (dl)-15-deoxy-16-hydroxy-16(alpha/beta)-vinyl-prostaglandin E2 methyl ester]: (II). Effects on the adrenergic nervous system. J Hypertens. 1986 Dec;4(6):749-57. PubMed PMID: 2880911. 3: Olsen EA, DeLong E. Transdermal viprostol in the treatment of male pattern baldness. J Am Acad Dermatol. 1990 Sep;23(3 Pt 1):470-2. PubMed PMID: 2212146. 4: Nicolau G, Cosulich DB, Tonelli A, Chen SM, Pruzinsky MS, Blum D. Metabolism of viprostol--a synthetic vasodilator PGE2 analog. Prostaglandins. 1986 Apr;31(4):811-27. PubMed PMID: 3088678. 5: Cervoni P, Chan PS. Synthetic stable orally and transdermally long-acting prostaglandin E2 (PGE2) congener (viprostol; CL 115,347) and prostacyclin congener (CL 115,999) as antihypertensive agents. Adv Prostaglandin Thromboxane Leukot Res. 1989;19:331-4. PubMed PMID: 2526492. 6: Olivari MT, Levine TB, Cohn JN. Evidence for a direct renal stimulating effect of prostaglandin E2 on renin release in patients with congestive heart failure. Circulation. 1986 Dec;74(6):1203-7. PubMed PMID: 3536150. 7: Belch JJ, O'Dowd A, Forbes CD, Sturrock RD. Platelet sensitivity to a prostacyclin analogue in systemic sclerosis. Br J Rheumatol. 1985 Nov;24(4):346-50. PubMed PMID: 2415199. 8: Lai FM, Tanikella TK, Cervoni P. The vasorelaxant effect of (+/-)-15-deoxy-16-hydroxy-16(alpha/beta)-vinyl-prostaglandin E2 (CL 115, 129) and its methyl ester (CL 115, 347) on the isolated ductus arteriosus preparation. Life Sci. 1984 May 7;34(19):1861-6. PubMed PMID: 6588286. 9: Lai FM, Cobuzzi A, Tanikella T, Cervoni P. Relaxant actions of viprostol and prostaglandin E2 on tracheal muscle and their effects on calcium influx. Prostaglandins. 1988 Jul;36(1):115-23. PubMed PMID: 3175022. 10: Chatziantoniou C, Arendshorst WJ. Prostaglandin interactions with angiotensin, norepinephrine, and thromboxane in rat renal vasculature. Am J Physiol. 1992 Jan;262(1 Pt 2):F68-76. PubMed PMID: 1733298. 11: Dunger DB, Dillon MJ, Daman-Willems C, Cooke ED, Bowcock SA. Treatment of childhood Raynaud's disease by transdermal prostaglandin E2 analogue. Lancet. 1985 Jul 6;2(8445):50. PubMed PMID: 2861505. 12: Birnbaum JE, Chan PS, Cervoni P, Dessy F, Van Humbeeck L. Cutaneous erythema and blood pressure lowering effects of topically applied 16-vinylprostaglandins. Prostaglandins. 1982 Feb;23(2):185-99. PubMed PMID: 7079519. 13: Crandall DL, Vu V, Lizzo FH, Davis BA, Cervoni P. Antilipolytic activity of viprostol, a transdermally active antihypertensive PGE2 analog. Prostaglandins. 1987 May;33(5):767-73. PubMed PMID: 2438724. 14: Burns EC, Dunger DB, Dillon MJ. Raynaud's disease. Arch Dis Child. 1985 Jun;60(6):537-41. PubMed PMID: 3160308; PubMed Central PMCID: PMC1777375. 15: Cervoni P, Chan PS, Lai FM, Birnbaum JE. CL 115,347 (DHV-PGE2 ME): a new orally and topically active prostaglandin antihypertensive agent. Fed Proc. 1983 Feb;42(2):157-61. PubMed PMID: 6571821. 16: Nicolau G, Baughman RA, Tonelli A, McWilliams W, Schiltz J, Yacobi A. Deposition of viprostol (a synthetic PGE2 vasodilator) in the skin following topical administration to laboratory animals. Xenobiotica. 1987 Sep;17(9):1113-20. PubMed PMID: 3120427. 17: Crandall DL, Goldstein BM, Gabel R, Lizzo FH, Cervoni P. Effects of the antihypertensive prostaglandin analog CL 115,347 on cardiac output distribution in the spontaneously hypertensive rat. J Cardiovasc Pharmacol. 1985 Sep-Oct;7(5):996-1002. PubMed PMID: 2413314. 18: Chatziantoniou C, Arendshorst WJ. Vascular interactions of prostaglandins with thromboxane in kidneys of rats developing hypertension. Am J Physiol. 1993 Aug;265(2 Pt 2):F250-6. PubMed PMID: 8396345. 19: Nicolau G, Dahlin DC, Kohlbrenner M, Chan PS, Ronsberg MA, Saunders TK, Yacobi A, Cervoni P. Skin metabolism and transdermal absorption of viprostol, a synthetic PGE2 analog, in the rat: effect of vehicle. Skin Pharmacol. 1989;2(1):22-9. PubMed PMID: 2627412. 20: Chatziantoniou C, Arendshorst WJ. Impaired ability of prostaglandins to buffer renal vasoconstriction in genetically hypertensive rats. Am J Physiol. 1992 Oct;263(4 Pt 2):F573-80. PubMed PMID: 1329556.